{"filing":{"accession_number":"0001193125-26-368710","cik":"0001885827","ticker":"VRAX","company_name":"Virax Biolabs Group Ltd","form":"6-K","filing_date":"2026-08-26","report_date":"2026-08-21","primary_document":"6-k_8.21.26_eagm_results.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1885827/000119312526368710/6-k_8.21.26_eagm_results.htm"},"events":[{"id":29783,"run_id":27281,"accession_number":"0001193125-26-368710","anchor_item_number":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The 6-K discloses results of an Extraordinary General Meeting held on August 21, 2026, where shareholders voted on two proposals: (1) approval of a Share Capital Increase from US$50,000 to US$12,500,000 (approved with 61,471 votes for, 54,414 against), and (2) adoption of amended articles of association (not approved, failing the two-thirds special resolution threshold with 66,754 for and 53,203 against). This is a direct disclosure of shareholder vote results under Item 5.07 equivalent, and the capital increase approval is material to investors as it substantially increases authorized shares from 2 million to 500 million.","company_name":"Virax Biolabs Group Ltd","ticker":"VRAX","filing_date":"2026-08-26","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":32167,"accession_number":"0001193125-26-368710","item_number":null,"item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The 6-K discloses results of an Extraordinary General Meeting held on August 21, 2026, where shareholders voted on two proposals: (1) approval of a Share Capital Increase from US$50,000 to US$12,500,000 (approved with 61,471 votes for, 54,414 against), and (2) adoption of amended articles of association (not approved, failing the two-thirds special resolution threshold with 66,754 for and 53,203 against). This is a direct disclosure of shareholder vote results under Item 5.07 equivalent, and the capital increase approval is material to investors as it substantially increases authorized shares from 2 million to 500 million.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-26T20:31:59.435144+00:00","company_name":"Virax Biolabs Group Ltd","ticker":"VRAX","filing_date":"2026-08-26"}]}